TNF-a SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.

Pharmacogenomics

PubMedID: 24798719

Franca R, Rebora P, Athanasakis E, Favretto D, Verzegnassi F, Basso G, Tommasini A, Valsecchi MG, Decorti G, Rabusin M. TNF-a SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype. Pharmacogenomics. 2014;15(5):619-27.
Aim: In the AIEOP-BFM ALL (Associazione Italiana Ematologia Oncologia Pediatrica-Berlin Frankfurt Münster acute lymphoblastic leukemia) 2000 protocol, 70% of relapsed patients had favorable prognostic features and fell within less intensive polychemotherapeutic regimens, suggesting the need for better assessing lower risk stratification. Materials & methods: A novel two-phase study design selected 614 children to be genotyped for TNF-a SNP rs1800629 (-308G>A). A weighted Cox model was applied to evaluate the SNP effect on hazard of relapse, adjusting for immunophenotype, risk group, age and gender and including interaction terms. Results: Significant interaction was found with immunophenotypes (p = 0.0007, with minor allele genotypes being adverse genetic markers in B-cell acute lymphoblastic leukemia and protective ones in T-cell acute lymphoblastic leukemia), and also with risk protocols (p = 0.0041, with minor allele genotypes as prognostic factor of relapse for standard risk patients [only one T-cell acute lymphoblastic leukemia in the subgroup analyzed]). Conclusion: The presence of at least one A allele in TNF-a SNP rs1800629 should suggest a closer monitoring in B-cell acute lymphoblastic leukemia standard risk patients. Original submitted 12 September 2013; Revision submitted 16 December 2013.